Can a genetic marker make rectal cancer treatment more precise?

NCT ID NCT06210971

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial is testing whether a combination of chemotherapy drugs (liposomal irinotecan and capecitabine) plus radiation, given before surgery, can help people with locally advanced rectal cancer. The treatment plan is personalized based on a genetic marker (UGT1A1) that affects how the body processes the drugs. The main goal is to see if this approach can lead to a complete disappearance of the tumor at the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
liposomal irinotecan and capecitabine combined with radiation therapy
What this could lead to
If successful, this approach could increase the chance of eliminating the tumor before surgery, potentially improving outcomes for rectal cancer patients.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not be conclusive. The treatment may cause side effects, and the genetic-guided dosing may not improve outcomes as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hebei Medical University Fourth Hospital

    Shijiazhuang, Hebei, 050000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.